Randomized trial · people

Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This large 80-week trial adds placebo-controlled evidence that retatrutide lowered weight and also eased knee osteoarthritis pain and sleep apnea events in adults with obesity.

Kind
Randomized trial
Studied in
People
Number studied
2339
Published
2026
Journal
N Engl J Med

What they tested

The team tested whether weekly retatrutide lowers body weight in adults with obesity, and whether it eases knee osteoarthritis pain and sleep apnea in those who had them.

How the study was done

A phase 3, randomized, double-blind, placebo-controlled trial in 2339 adults with obesity but no diabetes, who got a weekly shot of retatrutide (4 mg, 9 mg or 12 mg) or placebo, a dummy shot, for 80 weeks. Subgroups included 574 people with knee osteoarthritis and 243 with obstructive sleep apnea.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Mean body weight changed by -17.6% in the 4 mg arm, -23.7% in the 9 mg arm and -25.0% in the 12 mg arm, compared with -3.9% on placebo (P<0.001 for the 9 mg and 12 mg arms). In people with knee osteoarthritis, the WOMAC pain score (a 1 to 10 scale where higher means worse pain) fell by -3.2, -3.5 and -3.6 across the three arms versus -1.9 on placebo in the main analysis. In people with sleep apnea, the apnea-hypopnea index (breathing pauses or shallow-breathing events per hour) fell by -22.9, -34.3 and -31.7 events per hour versus -9.9 on placebo. Stomach and gut side effects were the most common.

What it doesn’t show

The trial included only adults without diabetes, and the knee and sleep apnea results come from smaller subgroups. It was funded by Eli Lilly.

The paper

Jastreboff et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo